BiotechTube
Home/Pipeline/Quemliclustat (AB680)

Quemliclustat (AB680)

Pancreatic Cancer

Phase 2/3Active

Key Facts

Indication
Pancreatic Cancer
Phase
Phase 2/3
Status
Active
Company
Arcus Biosciences

About Arcus Biosciences

Founded in 2015, Arcus Biosciences is a clinical-stage biopharma with a mission to develop best-in-class cancer therapies through its proprietary 'Combining to Cure®' philosophy. The company has built a fully integrated platform, advancing a deep pipeline targeting key immuno-oncology pathways like adenosine signaling and TIGIT. With strategic partnerships, including a major collaboration with Gilead Sciences, and multiple programs in late-stage development, Arcus is positioned as a significant player in the next wave of oncology combination treatments.

View full company profile

Therapeutic Areas

Oncology

Other Pancreatic Cancer Drugs

DrugCompanyPhase
Ampligen® (rintatolimod)AIM ImmunoTechEarly Access Program
HBM9027Harbour BioMedPhase 1
Small-Molecule TherapeuticAIkido LabsPre-clinical
SIMBs + ImmunotherapyAdvanced MicrobubblesPre-clinical
CLS-014CLS TherapeuticsPre-clinical
SOMA PlatformCoherence NeuroPre-clinical
NP-G2-044Novita PharmaceuticalsPhase 2a
Pancreatic Cancer TestMosaique DiagnosticDevelopment
Iontophoretic SystemContinuity BiosciencesPre-clinical
Lixumistat (IM156)ImmunoMet TherapeuticsPhase 1b
Electron IORTIntraop MedicalApproved
SBT-100Singh BiotechnologyPre-clinical